Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5
16 July 2021 - 6:15AM
Business Wire
Conference Call and Webcast Scheduled for 1:30
p.m. PDT
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company focused on novel therapies
for the treatment of glaucoma, corneal disorders and retinal
diseases, plans to release second quarter 2021 financial results
after the market close on Thursday, August 5, 2021. The company’s
management will discuss the results during a conference call and
simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 5,
2021.
A link to the live webcast will be available on the company’s
website at http://investors.glaukos.com. To participate in the
conference call, please dial 833-231-8262 (U.S.) or 647-689-4107
(International) and enter Conference ID 4248858. A replay will be
archived on the company’s website following completion of the
call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on novel therapies for the
treatment of glaucoma, corneal disorders and retinal diseases. The
company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to
revolutionize the traditional glaucoma treatment and management
paradigm. Glaukos launched the iStent®, its first MIGS device, in
the United States in 2012, its next-generation iStent inject®
device in the United States in 2018, and most recently, the iStent
inject W device in 2020. In corneal health, Glaukos’ proprietary
suite of single-use, bio-activated pharmaceuticals are designed to
strengthen, stabilize and reshape the cornea through a process
called corneal collagen cross-linking to treat corneal ectatic
disorders and correct refractive conditions. Glaukos is leveraging
its platform technology to build a comprehensive and proprietary
portfolio of micro-scale surgical and pharmaceutical therapies in
glaucoma, corneal health and retinal disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210715005772/en/
Chris Lewis Sr. Director, Investor Relations & Corporate
Strategy & Development (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Apr 2024 to May 2024
Glaukos (NYSE:GKOS)
Historical Stock Chart
From May 2023 to May 2024